Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Lonza Begins Manufacturing BNC101

By Pharmaceutical Processing | April 23, 2013

Bionomics Limited announced that it has initiated manufacturing activities for BNC101, its lead anti-cancer stem cell candidate following completion of key preclinical studies.

Dr Deborah Rathjen, Bionomics CEO & Managing Director commented, “The start of manufacturing activities for BNC101 signals a significant step towards clinical trials. We anticipate that Bionomics will commence clinical trials of BNC101 in 2014.”

“BNC101 is a novel therapeutic antibody designed to target cancer stem cells. Eliminating cancer stem cells represents a new cancer treatment paradigm that could offer a distinct advantage over existing treatment strategies and a solution for resistance to chemotherapy,” said Dr Rathjen.

Lonza will manufacture BNC101 at its facility in Slough, UK.

“We consider Lonza to be a leader in the area of contract development and manufacturing, and we are pleased to announce this important milestone in the BNC101 development program,” said Christopher Reyes, Ph.D., Vice President of Research and Development Biologics.

Preclinical data has shown that BNC101 has demonstrated functional activity against LGR5, a high value cancer stem cell receptor. In addition, BNC101 significantly reduces cancer stem cell frequency and prevents tumour re-growth in long term animal studies involving primary colorectal cancer patient samples with multiple underlying gene mutations.

The clinical strategy for BNC101 will target solid tumours expressing LGR5 where there is a high rate of relapse. Colorectal cancer and pancreatic cancer have been chosen as initial priority indications.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE